Figure 4.
Kaplan–Meier estimate of overall survival from start of second- or third-line treatment with EGFR antibodies, cetuximab (n=75), or panitumumab (n=7), in 82 patients with known RAS/BRAF status. Mut=mutation; WT=wild-type.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.